Company at a Glance
VIDEO
π Get full analytics about Astellas Pharma
Sign up for free
or
log in
π Discover "The Checklist Value Investor β A Smarter Way to Pick Stocks" β free eBook!
Price
Overview
Astellas Pharma is a Japanese pharmaceutical company that was created in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. The company focuses on the research, development, and commercialization of pharmaceutical products in a variety of therapeutic areas, including immunology, oncology, and urology. One of Astellas Pharma's primary areas of focus is in the development of treatments for oncology-related diseases. They have a strong portfolio of oncology products, including treatments for prostate, bladder, and pancreatic cancer. In addition, the company is also committed to developing treatments for rare diseases, such as Duchenne muscular dystrophy and acute myeloid leukemia. Astellas Pharma also has a global presence, with operations in Asia, Europe, North America, and Latin America. They operate research and development centers in Japan, the United States, and the Netherlands, as well as manufacturing facilities in various countries. Overall, Astellas Pharma is dedicated to improving the health and well-being of patients worldwide through the development of innovative and effective pharmaceutical products.
What is special about the company?
π Want to read more about Astellas Pharma?
Sign up for free
or
log in
π Discover "The Checklist Value Investor β A Smarter Way to Pick Stocks" β free eBook!
VGhlcmUgYX JlIGEgZmV3 IHRoaW5ncy B0aGF0IGFy ZSBzcGVjaW FsIGFib3V0 IEFzdGVsbG FzIFBoYXJt YSBhcyBhIG NvbXBhbnk6 PGJyPjEuIF N0cmVuZ3Ro IGluIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudDog QXN0ZWxsYX MgUGhhcm1h IGhhcyBhIH N0cm9uZyBm b2N1cyBvbi ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQsIHdpdG ggYSBzaWdu aWZpY2FudC Bwb3J0aW9u IG9mIGl0cy ByZXZlbnVl cyBiZWluZy BpbnZlc3Rl ZCBpbiB0aG lzIGFyZWEu IFRoaXMgaG FzIGFsbG93 ZWQgdGhlbS B0byBkZXZl bG9wIGlubm 92YXRpdmUg bWVkaWNpbm VzIGFuZCB0 cmVhdG1lbn RzIGZvciBh IHdpZGUgcm FuZ2Ugb2Yg aWxsbmVzc2 VzIGFuZCBj b25kaXRpb2 5zLjxicj4y LiBHbG9iYW wgcHJlc2Vu Y2U6IEFzdG VsbGFzIFBo YXJtYSBpcy BhIHRydWx5 IGdsb2JhbC Bjb21wYW55 LCB3aXRoIG xvY2F0aW9u cyBhbmQgb3 BlcmF0aW9u cyBpbiBvdm VyIDUwIGNv dW50cmllcy B3b3JsZHdp ZGUuIFRoaX MgaGFzIGVu YWJsZWQgdG hlbSB0byBy ZWFjaCBhIG Jyb2FkIG1h cmtldCBhbm QgcHJvdmlk ZSB0aGVpci Bwcm9kdWN0 cyBhbmQgc2 VydmljZXMg dG8gYSBkaX ZlcnNlIHJh bmdlIG9mIH BhdGllbnQg cG9wdWxhdG lvbnMuPGJy PjMuIFBhdG llbnQtY2Vu dHJpYyBhcH Byb2FjaDog QXN0ZWxsYX MgUGhhcm1h IHByaW9yaX RpemVzIHRo ZSBuZWVkcy BhbmQgd2Vs bC1iZWluZy BvZiBwYXRp ZW50cyBhYm 92ZSBhbGwg ZWxzZS4gVG hleSBzdHJp dmUgdG8gdW 5kZXJzdGFu ZCB0aGUgbm VlZHMgb2Yg cGF0aWVudH MgYW5kIHdv cmsgdG8gZG V2ZWxvcCB0 cmVhdG1lbn RzIHRoYXQg YWRkcmVzcy B0aGVpciBz cGVjaWZpYy Bjb25kaXRp b25zLjxicj 40LiBDb21t aXRtZW50IH RvIHN1c3Rh aW5hYmlsaX R5OiBUaGUg Y29tcGFueS BoYXMgYSBz dHJvbmcgY2 9tbWl0bWVu dCB0byBzdX N0YWluYWJp bGl0eSwgaW 1wbGVtZW50 aW5nIGVjby 1mcmllbmRs eSBwcmFjdG ljZXMgYW5k IGluaXRpYX RpdmVzIGlu IGl0cyBvcG VyYXRpb25z IGFuZCBwcm 9kdWN0aW9u IHByb2Nlc3 Nlcy4gVGhl eSBhbHNvIH dvcmsgdG8g ZW5zdXJlIG V0aGljYWwg YW5kIHJlc3 BvbnNpYmxl IGJ1c2luZX NzIHByYWN0 aWNlcy48Yn I+NS4gQ29s bGFib3JhdG l2ZSBwYXJ0 bmVyc2hpcH M6IEFzdGVs bGFzIFBoYX JtYSBiZWxp ZXZlcyBpbi Bjb2xsYWJv cmF0aW9uIG FuZCB3b3Jr aW5nIHdpdG ggb3RoZXIg Y29tcGFuaW VzLCBvcmdh bml6YXRpb2 5zLCBhbmQg aW5kaXZpZH VhbHMgdG8g YWNoaWV2ZS B0aGVpciBt aXNzaW9uIG 9mIGltcHJv dmluZyB0aG UgbGl2ZXMg b2YgcGF0aW VudHMuIFRo ZXkgaGF2ZS Bmb3JtZWQg cGFydG5lcn NoaXBzIHdp dGggdmFyaW 91cyBhY2Fk ZW1pYyBpbn N0aXR1dGlv bnMsIHJlc2 VhcmNoIG9y Z2FuaXphdG lvbnMsIGFu ZCBvdGhlci BwaGFybWEg Y29tcGFuaW VzIHRvIGFk dmFuY2UgaG VhbHRoY2Fy ZSBpbm5vdm F0aW9uLjxi cj42LiBDb3 Jwb3JhdGUg c29jaWFsIH Jlc3BvbnNp YmlsaXR5Oi BBc3RlbGxh cyBQaGFybW EgaXMgY29t bWl0dGVkIH RvIGdpdmlu ZyBiYWNrIH RvIHRoZSBj b21tdW5pdH kgYW5kIGlt cHJvdmluZy BwZW9wbGUn cyBsaXZlcy B0aHJvdWdo IGl0cyBjb3 Jwb3JhdGUg c29jaWFsIH Jlc3BvbnNp YmlsaXR5IG luaXRpYXRp dmVzLiBUaG lzIGluY2x1 ZGVzIGludm VzdGluZyBp biBlZHVjYX Rpb24sIHBy b21vdGluZy BlbXBsb3ll ZSBkaXZlcn NpdHkgYW5k IGluY2x1c2 lvbiwgYW5k IHN1cHBvcn RpbmcgbG9j YWwgY29tbX VuaXRpZXMu
What the company's business model?
π Want to read more about Astellas Pharma?
Sign up for free
or
log in
π Get insights from "The Checklist Value Investor β A Smarter Way to Pick Stocks" now!
QXN0ZWxsYX MgUGhhcm1h IGlzIGEgZ2 xvYmFsIHBo YXJtYWNldX RpY2FsIGNv bXBhbnkgdG hhdCBmb2N1 c2VzIG9uIG RldmVsb3Bp bmcsIG1hbn VmYWN0dXJp bmcsIGFuZC BtYXJrZXRp bmcgaW5ub3 ZhdGl2ZSBh bmQgaGlnaC 1xdWFsaXR5 IG1lZGljaW 5lcyBmb3Ig dGhlIHRyZW F0bWVudCBv ZiB2YXJpb3 VzIGRpc2Vh c2VzIGFuZC Bjb25kaXRp b25zLiBJdH MgYnVzaW5l c3MgbW9kZW wgcmV2b2x2 ZXMgYXJvdW 5kIHRoZSBm b2xsb3dpbm cga2V5IGFz cGVjdHM6PG JyPjEuIFJl c2VhcmNoIG FuZCBEZXZl bG9wbWVudC AoUiZEKTog QXN0ZWxsYX MgUGhhcm1h IGludmVzdH MgaGVhdmls eSBpbiBSJk QgdG8gZGlz Y292ZXIgYW 5kIGRldmVs b3AgbmV3IG RydWdzIGFu ZCB0cmVhdG 1lbnRzLiBU aGUgY29tcG FueSBoYXMg YSBnbG9iYW wgbmV0d29y ayBvZiByZX NlYXJjaCBj ZW50ZXJzIG FuZCBlbXBs b3lzIGEgdG VhbSBvZiBz Y2llbnRpc3 RzIGFuZCBy ZXNlYXJjaG VycyB3aG8g d29yayBjb2 xsYWJvcmF0 aXZlbHkgdG 8gaWRlbnRp ZnkgYW5kIG RldmVsb3Ag cG90ZW50aW FsIGRydWcg Y2FuZGlkYX Rlcy48YnI+ Mi4gU3RyYX RlZ2ljIFBh cnRuZXJzaG lwcyBhbmQg Q29sbGFib3 JhdGlvbnM6 IEFzdGVsbG FzIFBoYXJt YSBjb2xsYW JvcmF0ZXMg d2l0aCBvdG hlciBwaGFy bWFjZXV0aW NhbCBjb21w YW5pZXMsIG FjYWRlbWlj IGluc3RpdH V0aW9ucywg YW5kIHJlc2 VhcmNoIG9y Z2FuaXphdG lvbnMgdG8g YWNjZXNzIG 5ldyB0ZWNo bm9sb2dpZX MsIHNoYXJl IGtub3dsZW RnZSwgYW5k IGFkdmFuY2 UgaXRzIFIm RCBlZmZvcn RzLiBUaGUg Y29tcGFueS BhbHNvIHNl ZWtzIHRvIG FjcXVpcmUg b3IgbGljZW 5zZSBwcm9t aXNpbmcgY2 9tcG91bmRz IGFuZCB0ZW Nobm9sb2dp ZXMgZnJvbS BleHRlcm5h bCBzb3VyY2 VzIHRvIGV4 cGFuZCBpdH MgcHJvZHVj dCBwaXBlbG luZS48YnI+ My4gTWFudW ZhY3R1cmlu ZyBhbmQgU3 VwcGx5IENo YWluOiBBc3 RlbGxhcyBQ aGFybWEgaG FzIGEgZ2xv YmFsIG1hbn VmYWN0dXJp bmcgYW5kIH N1cHBseSBu ZXR3b3JrIH RoYXQgcHJv ZHVjZXMgYW 5kIGRpc3Ry aWJ1dGVzIG l0cyBwcm9k dWN0cyB0by B2YXJpb3Vz IG1hcmtldH Mgd29ybGR3 aWRlLiBUaG UgY29tcGFu eSBlbnN1cm VzIHRoZSBo aWdoZXN0IH N0YW5kYXJk cyBvZiBxdW FsaXR5IGFu ZCBjb21wbG lhbmNlIGlu IGl0cyBtYW 51ZmFjdHVy aW5nIHByb2 Nlc3NlcyB0 byBtZWV0IH JlZ3VsYXRv cnkgcmVxdW lyZW1lbnRz Ljxicj40Li BNYXJrZXRp bmcgYW5kIF NhbGVzOiBB c3RlbGxhcy BQaGFybWEg bWFya2V0cy BpdHMgcHJv ZHVjdHMgdG hyb3VnaCBh IG5ldHdvcm sgb2Ygc2Fs ZXMgcmVwcm VzZW50YXRp dmVzIHRvIG hlYWx0aGNh cmUgcHJvZm Vzc2lvbmFs cyBhbmQgaG 9zcGl0YWxz LiBUaGUgY2 9tcGFueSB1 c2VzIHZhcm lvdXMgbWFy a2V0aW5nIH N0cmF0ZWdp ZXMgdG8gcm Fpc2UgYXdh cmVuZXNzIG FuZCBwcm9t b3RlIGl0cy Bwcm9kdWN0 cywgaW5jbH VkaW5nIHRy YWRpdGlvbm FsIGFkdmVy dGlzaW5nLC BtZWRpY2Fs IGNvbmZlcm VuY2VzLCBh bmQgZWR1Y2 F0aW9uYWwg cHJvZ3JhbX MuPGJyPjUu IEdsb2JhbC BHcm93dGgg YW5kIEV4cG Fuc2lvbjog QXN0ZWxsYX MgUGhhcm1h IGhhcyBhIG ZvY3VzZWQg YXBwcm9hY2 ggdG8gZXhw YW5kIGl0cy BnbG9iYWwg Zm9vdHByaW 50IGJ5IGVu dGVyaW5nIG 5ldyBtYXJr ZXRzLCBwYX J0aWN1bGFy bHkgaW4gZW 1lcmdpbmcg ZWNvbm9taW VzLCBhbmQg ZGl2ZXJzaW Z5aW5nIGl0 cyBwcm9kdW N0IHBvcnRm b2xpby4gVG hlIGNvbXBh bnkgYWxzby BzZWVrcyB0 byBlc3RhYm xpc2ggcGFy dG5lcnNoaX BzIHdpdGgg bG9jYWwgY2 9tcGFuaWVz IHRvIHN0cm VuZ3RoZW4g aXRzIHByZX NlbmNlIGlu IGRpZmZlcm VudCByZWdp b25zLjxicj 42LiBDb3Jw b3JhdGUgU2 9jaWFsIFJl c3BvbnNpYm lsaXR5IChD U1IpOiBBc3 RlbGxhcyBQ aGFybWEgaX MgY29tbWl0 dGVkIHRvIG dpdmluZyBi YWNrIHRvIH NvY2lldHkg YW5kIGZvc3 RlcmluZyBz dXN0YWluYW JsZSBncm93 dGggaW4gdG hlIGNvbW11 bml0aWVzIG l0IHNlcnZl cy4gVGhlIG NvbXBhbnkn cyBDU1IgcH JvZ3JhbXMg Zm9jdXMgb2 4gc3VwcG9y dGluZyBoZW FsdGhjYXJl IGluaXRpYX RpdmVzLCBw cm9tb3Rpbm cgZW52aXJv bm1lbnRhbC BzdXN0YWlu YWJpbGl0eS wgYW5kIGlu dmVzdGluZy BpbiBsb2Nh bCBjb21tdW 5pdGllcy48 YnI+SW4gc3 VtbWFyeSwg QXN0ZWxsYX MgUGhhcm1h J3MgYnVzaW 5lc3MgbW9k ZWwgcmV2b2 x2ZXMgYXJv dW5kIGludm VzdGluZyBp biBSJkQsIH N0cmF0ZWdp YyBwYXJ0bm Vyc2hpcHMg YW5kIGNvbG xhYm9yYXRp b25zLCBhIG dsb2JhbCBt YW51ZmFjdH VyaW5nIGFu ZCBzdXBwbH kgY2hhaW4s IG1hcmtldG luZyBhbmQg c2FsZXMsIG dsb2JhbCBn cm93dGggYW 5kIGV4cGFu c2lvbiwgYW 5kIGNvcnBv cmF0ZSBzb2 NpYWwgcmVz cG9uc2liaW xpdHkuIEJ5 IGZvbGxvd2 luZyB0aGlz IG1vZGVsLC B0aGUgY29t cGFueSBhaW 1zIHRvIG9m ZmVyIGlubm 92YXRpdmUg YW5kIGhpZ2 gtcXVhbGl0 eSBtZWRpY2 luZXMgdG8g aW1wcm92ZS BwYXRpZW50 IG91dGNvbW VzIGFuZCBj cmVhdGUgbG 9uZy10ZXJt IHZhbHVlIG ZvciBpdHMg c3Rha2Vob2 xkZXJzLg==
Interesting facts about the company
π Want to read more about Astellas Pharma?
Sign up for free
or
log in
π Donβt miss "The Checklist Value Investor β A Smarter Way to Pick Stocks" β free!
CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvS1 dxd2ZzYzh1 dVgyZmh6NX h2TUIud2Vi cCIgYWx0PS JBc3RlbGxh cyBQaGFybW EiIHRpdGxl PSJBc3RlbG xhcyBQaGFy bWEiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgQXN0 ZWxsYXMgUG hhcm1hPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TmCBDbGFp bSB5b3VyIG ZyZWUgZUJv b2s6IDxpPi JUaGUgQ2hl Y2tsaXN0IF ZhbHVlIElu dmVzdG9yIO KAlCBBIFNt YXJ0ZXIgV2 F5IHRvIFBp Y2sgU3RvY2 tzIjwvaT4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9wPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPCEtLQog ICAgICAgIC AgICAgICAg ICAgICAgIC A8ZGl2IHN0 eWxlPSdtYX JnaW4tdG9w OiAxMnB4Oy Bmb250LXNp emU6IDEzcH g7IGNvbG9y OiAjNDQ0Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BTaWduIHVw IG5vdyBhbm QgZ2V0IG91 ciBmcmVlIG VCb29rIAog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgPGI+ VGhlIENoZW NrbGlzdCBW YWx1ZSBJbn Zlc3RvciDi gJQgQSBTbW FydGVyIFdh eSB0byBQaW NrIFN0b2Nr czwvYj4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IC0tPgogIC AgICAgICAg ICAgICAgIC AgICAgICA8 IS0tCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxk aXYgc3R5bG U9J21hcmdp bi10b3A6ID E2cHg7IGZv bnQtc2l6ZT ogMTRweDsg Y29sb3I6IC M0NDQ7IGZv bnQtZmFtaW x5OiAtYXBw bGUtc3lzdG VtLCBCbGlu a01hY1N5c3 RlbUZvbnQs IFNlZ29lIF VJLCBSb2Jv dG8sIEhlbH ZldGljYSBO ZXVlLCBzYW 5zLXNlcmlm OyBsaW5lLW hlaWdodDog MS42Oyc+Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBIYX ZlIHlvdSBo ZWFyZCBhYm 91dCBvdXIg c2hvcnQgPH N0cm9uZyBz dHlsZT0nZm 9udC13ZWln aHQ6IDYwMD snPkRhaWx5 IFZpZGVvIE 5ld3NsZXR0 ZXI8L3N0cm 9uZz4/CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdodH RwczovL3d3 dy5pbnNpZ2 h0ZnVsdmFs dWUuY29tL2 5ld3NsZXR0 ZXIucGhwJy B0YXJnZXQ9 J19ibGFuay cgc3R5bGU9 J2NvbG9yOi AjMDA3QkZG OyB0ZXh0LW RlY29yYXRp b246IG5vbm U7IGZvbnQt d2VpZ2h0Oi A1MDA7IG1h cmdpbi1sZW Z0OiA2cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBGaW 5kIG91dCBt b3JlCiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8L2E+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAgIC AgICAgICAg ICAtLT4KIC AgICAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgCiAg ICAgICAgCi AgICAgICAg PHNwYW4gY2 xhc3M9J2Js dXJyZWQtdG V4dCc+CiAg ICAgICAgIC AgIE1TNGdR WE4wWlcgeH NZWE1nVUdo aCBjbTFoSU hkaGN5IEJt YjNKdFpXUW cgYVc0Z01q QXdOUyBCMG FISnZkV2Rv IElIUm9aU0 J0WlggSm5a WElnYjJZZy BkSGR2SUVw aGNHIEZ1Wl hObElIQm8g WVhKdFlXTm xkWCBScFky RnNJR052IG JYQmhibWxs Y3kgd2dXV0 Z0WVc1diBk V05vYVNCUW FHIEZ5YldG alpYVjAgYV dOaGJDQkRi eSA0Z1lXNW tJRVoxIGFt bHpZWGRoSU YgQm9ZWEp0 WVdObCBkWF JwWTJGc0lF IE52TGp4aW NqNHkgTGlC VWFHVWdZMi A5dGNHRnVl ZUtBIG1YTW daMnh2WW0g RnNJR2hsWV dSeCBkV0Z5 ZEdWeWN5IE JwY3lCc2Iy TmggZEdWa0 lHbHVJRiBS dmEzbHZMQ0 JLIFlYQmhi aXdnWW4gVj BJR2wwSUdG cyBjMjhnYU dGeklHIEVn YzJsbmJtbG 0gYVdOaGJu UWdjSCBKbG MyVnVZMlVn IGFXNGdiM1 JvWlggSWdZ MjkxYm5SeS BhV1Z6SUhO MVkyIGdnWV hNZ2RHaGwg SUZWdWFYUm xaQyBCVGRH RjBaWE1zIE lFVjFjbTl3 WlMgd2dZVz VrSUVGeiBh V0V1UEdKeV BqIE11SUVG emRHVnMgYk dGeklITnda VyBOcFlXeH BlbVZ6IElH bHVJR1JsZG 0gVnNiM0Jw Ym1jZyBZVz VrSUcxaGJu IFZtWVdOMG RYSnAgYm1j Z2JXVmthVy BOcGJtVnpJ R2x1IElITm xkbVZ5WVcg d2dkR2hsY2 1GdyBaWFYw YVdNZ1lYIE psWVhNc0lH bHUgWTJ4MV pHbHVaeSBC MWNtOXNiMm Q1IExDQnZi bU52YkcgOW 5lU3dnYVcx dCBkVzV2Yk c5bmVTIHdn WVc1a0lHbH UgWm1WamRH bHZkWCBNZ1 pHbHpaV0Z6 IFpYTXVQR0 p5UGogUXVJ RlJvWlNCdS BZVzFsSUVG emRHIFZzYk dGeklHbHog SUdSbGNtbD JaVyBRZ1pu SnZiU0IwIG FHVWdSM0ps Wlcgc2dkMj l5WkhNZyBZ WE4wWlhJc0 lHIDFsWVc1 cGJtY2cgYz NSaGNpd2dZ VyA1a0lHeH ZaMjl6IExD QnRaV0Z1YV cgNW5JSGR2 Y21RZyBiM0 lnYldWemMy IEZuWlN3Z2 NtVncgY21W elpXNTBhVy A1bklIUm9a U0JqIGIyMX dZVzU1NG8g Q1pjeUJqYj IxdCBhWFJ0 Wlc1MElIIF J2SUhOb2FX NXAgYm1jZ1 lTQnNhVyBk b2RDQnZiaU J1IFpYY2dh V1JsWVggTW dZVzVrSUdK eSBhVzVuYV c1bklIIFJv WlcwZ2RHOG cgYkdsbVpT NDhZbiBJK0 5TNGdTVzRn IFlXUmthWF JwYjIgNGdk RzhnY0doaC BjbTFoWTJW MWRHIGxqWV d4ekxDQkIg YzNSbGJHeG hjeSBCaGJI TnZJR2hoIG N5QmhJSE4w Y20gOXVaeU JtYjJOMSBj eUJ2YmlCeV pXIGRsYm1W eVlYUnAgZG 1VZ2JXVmth VyBOcGJtVW dZVzVrIElH bHpJR0ZqZE cgbDJaV3g1 SUdsdSBkbV Z6ZEdsdVp5 IEJwYmlCem RHVnQgSUdO bGJHd2djbS BWelpXRnlZ MmdnIFlXNW tJSFJsWTIg aHViMnh2Wj NrdSBQR0p5 UGpZdUlFIE Z6ZEdWc2JH RnogSUdoaG N5QmlaVyBW dUlISmxZMj luIGJtbDZa V1FnWm0gOX lJR2wwY3lC eiBkWE4wWV dsdVlXIEpw YkdsMGVTQm wgWm1admNu UnpMQyBCcG JtTnNkV1Jw IGJtY2dZbV ZwYm0gY2di bUZ0WldRZy BiMjVsSUc5 bUlIIFJvWl NCWGIzSnMg Wk9LQW1YTW dUVyA5emRD QkZkR2hwIF kyRnNJRU52 YlggQmhibW xsY3lCaSBl U0IwYUdVZ1 JYIFJvYVhO d2FHVnkgWl NCSmJuTjBh WCBSMWRHVW dabTl5IElI TmxkbVZ5WV cgd2dZMjl1 YzJWaiBkWF JwZG1VZ2VX IFZoY25NdV BHSnkgUGpj dUlGUm9aUy BCamIyMXdZ VzU1IElHbH pJR052Ylcg MXBkSFJsWk NCMCBieUJu YVhacGJtIG NnWW1GamF5 QjAgYnlCMG FHVWdZMiA5 dGJYVnVhWF JwIFpYTWdh WFFnYzIgVn lkbVZ6SUhS byBjbTkxWj JnZ2RtIEZ5 YVc5MWN5Qm ogYjNKd2Iz SmhkRyBVZ2 MyOWphV0Zz IElISmxjM0 J2Ym4gTnBZ bWxzYVhSNS BJSEJ5YjJk eVlXIDF6TE NCcGJtTnMg ZFdScGJtY2 djMyBWd2NH OXlkR2x1IF p5Qm9aV0Zz ZEcgaGpZWE psSUdGaiBZ MlZ6Y3lCaG JtIFFnWldS MVkyRjAgYV c5dUlHbHVh WCBScFlYUn BkbVZ6IExq eGljajQ0TG kgQkpiaUF5 TURBNCBMQ0 JCYzNSbGJH IHhoY3lCaV pXTmggYldV Z2RHaGxJRy BacGNuTjBJ SEJvIFlYSn RZV05sZFgg UnBZMkZzSU dOdiBiWEJo Ym5rZ2RHID hnY0dGeWRH NWwgY2lCM2 FYUm9JSCBS b1pTQkpibl JsIGNtNWhk R2x2Ym0gRn NJRk53WVdO bCBJRk4wWV hScGIyIDRn S0VsVFV5a2 cgVG1GMGFX OXVZVyB3Z1 RHRmliM0po IGRHOXllU3 dnWTIgOXVa SFZqZEdsdS BaeUJ5WlhO bFlYIEpqYU NCdmJpQmgg Ym5ScExXTm hibSBObGNp QmtjblZuIG N5QnBiaUJ0 YVcgTnliMm R5WVhacCBk SGt1UEdKeV BqIGt1SUVG emRHVnMgYk dGeklHaGhj eSBCaElITj BjbTl1IFp5 QndhWEJsYk cgbHVaU0J2 WmlCdSBaWG NnWVc1a0lH IGx1Ym05Ml lYUnAgZG1V Z2RISmxZWC BSdFpXNTBj eXdnIGQybD BhQ0J2ZG0g VnlJRGN3SU dOcyBhVzVw WTJGc0lIIF J5YVdGc2N5 QmogZFhKeV pXNTBiSCBr Z2RXNWtaWE ozIFlYa2dk Mjl5YkcgUj NhV1JsTGp4 aSBjajR4TU M0Z1ZHIGhs SUdOdmJYQm ggYm5rZ2FH RnpJSCBKbF kyVnBkbVZr IElHNTFiV1 Z5YjMgVnpJ R0YzWVhKay BjeUJoYm1R Z2NtIFZqYj JkdWFYUnAg YjI1eklHWn ZjaSBCcGRI TWdjSEp2IF pIVmpkSE1z SUggSmxjMl ZoY21ObyBM Q0JoYm1RZ1 luIFZ6YVc1 bGMzTWcgYj NCbGNtRjBh VyA5dWN5d2 dhVzVqIGJI VmthVzVuSU cgSmxhVzVu SUc1aCBiV1 ZrSUc5dVpT IEJ2WmlCMG FHVWcgVkc5 d0lEVXdJRS BOdmJYQmhi bWxsIGN5Qm 1iM0lnUkcg bDJaWEp6YV hSNSBJR0o1 SUVScGRtIF Z5YzJsMGVV bHUgWXk0PQ ogICAgICAg IDwvc3Bhbj 4KICAgICAg ICAKICAgIC AgICA=
See Company Q&A
π Get full analytics about Astellas Pharma
Sign up for free
or
log in
βοΈ Sign up to get "The Checklist Value Investor β A Smarter Way to Pick Stocks" for free